COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA IN CANADA

被引：0
|
作者：
Lachaine, J. [1 ]
Beauchemin, C. [1 ]
Mathurin, K. [1 ]
Aissa, F. [2 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
[2] Lundbeck Canada Inc, Montreal, PQ, Canada
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A141 / A142
页数：2
相关论文
共 50 条
  • [1] Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    Witzig, TE
    Flinn, IW
    Gordon, LI
    Emmanouilides, C
    Czuczman, MS
    Saleh, MN
    Cripe, L
    Wiseman, G
    Olejnik, T
    Multani, PS
    White, CA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3262 - 3269
  • [2] Introduction: Treatment of patients with rituximab-refractory indolent non-hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S1 - S1
  • [3] COST-EFFECTIVENESS OF BENDAMUSTINE plus RITUXIMAB VERSUS FLUDARABINE plus RITUXIMAB IN THE TREATMENT OF RELAPSED INDOLENT NON-HODGKIN'S AND MANTLE CELL LYMPHOMAS IN CANADA
    Lachaine, J.
    Beauchemin, C.
    Mathurin, K.
    Aissa, F.
    VALUE IN HEALTH, 2013, 16 (03) : A141 - A141
  • [4] Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
    Dennie, Trevor W.
    Kolesar, Jill M.
    CLINICAL THERAPEUTICS, 2009, 31 : 2290 - 2311
  • [5] Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-Cell non-Hodgkin lymphoma
    Kahl, Brad
    Bartlett, Nancy L.
    Leonard, John P.
    Ganjoo, Kristen
    Williams, Michael E.
    Czuczman, Myron S.
    Robinson, K. Sue
    Joyce, Robin
    van der Jagt, Richard H.
    Cheson, Bruce D.
    BLOOD, 2007, 110 (11) : 406A - 407A
  • [6] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE-RITUXIMAB TREATMENT COMPARED WITH FLUDARABINE-RITUXIMAB TREATMENT, IN PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA IN PANAMA
    Desanvicente-Celis, Z.
    Obando, C. A.
    Rodriguez, E.
    Gonzalez, L.
    Muschett, D.
    VALUE IN HEALTH, 2014, 17 (03) : A83 - A83
  • [7] Cost of 90Y-ibritumomab tiuxetan radioimmunotherapy versus cost of standard regimens for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma in Switzerland
    Frei, Andreas
    Delmore, Geoffrey
    Hitz, Felicitas
    Schwenkglenks, Matthias
    Szucs, Thomas
    BLOOD, 2007, 110 (11) : 975A - 975A
  • [8] Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy for indolent non-Hodgkin lymphoma
    Iino, Masaki
    Yamamoto, Takeo
    Sato, Tomoya
    Sakamoto, Yuma
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial
    Ujjani, Chaitra
    Cheson, Bruce
    FUTURE ONCOLOGY, 2011, 7 (01) : 9 - 14
  • [10] Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
    Cheson, Bruce D.
    Friedberg, Jonathan W.
    Kahl, Brad S.
    Van der Jagt, Richard H.
    Tremmel, Lothar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (06): : 452 - 457
12345